Label Changes for:

Dipentum (olsalazine sodium) 250 mg capsules

August 2009

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2009

ADVERSE REACTIONS

Postmarketing
  • addition of new safety information
Hide
(web4)